Loading
P2
Paragon 28, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by DaCosta Albert, was filed 18 Mar 2024.
Paragon 28, Inc.: what insiders have been doing
Paragon 28, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at Paragon 28, Inc. has published a filing in the past twelve months. The most recent one dates from 21 April 2025.
The full history, which starts in 2021, counts 2 purchases against 118 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
242
Thresholds
n/a
Buy Volume
€477,821
2 ops. · all time
Sell Volume
€118M
118 ops. · all time
Who traded when
BuySaleMVM Partners, LLC18 sales
Kristina Wright3 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$220.6M
Gross profitUS$164.9M75% margin
Net income-US$47M-21.3% margin
Last declaration on 21 April 2025
Declarations242 total
3,277,408 sharesCommon StockSEC:0000950170-25-056358:1
2,061,702 sharesCommon StockSEC:0000950170-25-056358:2
5,000,000 sharesCommon StockSEC:0000950170-25-056358:3
100,000 sharesCommon StockSEC:0000950170-25-056358:4
42,113 sharesCommon StockSEC:0000950170-25-056369:0
50,554 sharesCommon StockSEC:0000950170-25-056364:0
45,035 sharesCommon StockSEC:0000950170-25-056368:0
51,935 sharesCommon StockSEC:0000950170-25-056359:0
520,657 sharesCommon StockSEC:0000950170-25-056363:0
1,314,614 sharesCommon StockSEC:0000950170-25-056358:0
203,134 sharesCommon StockSEC:0000950170-25-056370:0
575,320 sharesCommon StockSEC:0000950170-25-056365:0
47,347 sharesCommon StockSEC:0000950170-25-056366:0
126,397 sharesCommon StockSEC:0000950170-25-056361:0
40,216 sharesCommon StockSEC:0000950170-25-056367:0
74,307 sharesCommon StockSEC:0000950170-25-056357:0
32,118 sharesCommon StockSEC:0000950170-25-056360:0
337,682 shares0Common StockSEC:0001610717-25-000089:0
145,817 shares0Common StockSEC:0001610717-25-000093:0
49,884 shares0Common StockSEC:0001610717-25-000092:0
117,344 shares0Common StockSEC:0001610717-25-000091:0
90,867 shares0Common StockSEC:0001610717-25-000090:0
2,061,702 shares0Common StockSEC:0001610717-25-000072:1
2,061,702 shares0Common StockSEC:0001610717-25-000072:0
1,044,295 shares@ US$13.040552.4% of flowCommon StockSEC:0001104659-25-023576:0
25 of 242 declarations
About Paragon 28, Inc.
Paragon 28, Inc. is a U.S.-based medical device company focused almost entirely on the foot and ankle orthopedic market. The company was listed on the NYSE under the ticker FNA and was headquartered in Englewood, Colorado, United States. Founded in 2010, Paragon 28 was built around a highly specialized strategy: concentrate product development, clinical education, and surgical instrumentation on a single, anatomically defined segment of orthopedics rather than competing as a broad-based implant manufacturer.
Its business model centers on a comprehensive portfolio of foot and ankle solutions, including plates and plating systems, screws, staples, nails, fracture-fixation devices, forefoot products, ankle systems, solutions for progressive collapsing foot deformity (PCFD) and flatfoot, Charcot foot offerings, orthobiologics, and related surgical instrumentation. The company’s approach is procedure-driven, meaning its products are designed around the actual surgical workflows used by foot and ankle specialists. That positioning is intended to improve reproducibility, simplify procedures, and support better clinical outcomes.
Read moreShow less
From a competitive standpoint, Paragon 28 occupied a niche but strategically attractive segment within orthopedics. It competed against much larger diversified medtech groups, yet its narrow focus gave it a differentiating edge in product depth, surgeon relationships, and innovation cadence. For investors, that specialization can be an advantage because it supports brand credibility and clinical expertise; at the same time, it requires continued commercial execution to expand penetration across hospitals and ambulatory settings.
Recent company news highlighted continued product innovation. In 2024 and early 2025, Paragon 28 announced new launches and expanded offerings in trauma and fixation, reinforcing its position in complex foot and ankle care. A major corporate development came in January 2025, when Zimmer Biomet announced a definitive agreement to acquire Paragon 28, and the transaction was subsequently completed in April 2025. As a result, Paragon 28 became a wholly owned subsidiary of Zimmer Biomet, marking a significant strategic consolidation in the orthopedics sector.
For market context, Paragon 28’s history as a public company on the NYSE in the United States is important: it reflects both the scale reached by the platform and the strategic value of its specialized portfolio. Before the acquisition closed, the company had also indicated a commercial footprint extending beyond the U.S., supporting international surgeon adoption and broader market access. Overall, Paragon 28 represents a focused orthopedics franchise built on foot-and-ankle expertise, product innovation, and a strong procedural offering.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
